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Abstract
Anticoagulant drugs directly or indirectly influence coagulation factors preventing fibrin
formation thus preventing blot clotting. They are classified into two groups according to
the mode of application, namely parenteral and oral drugs. Among the latter, vitamin K
antagonists (most often warfarin) were the only available oral drugs and were widely
used for almost a century. In the recent years, new oral anticoagulant drugs became
available that directly target either factor IIa or Xa. This chapter provides an overview of
both parenteral and oral anticoagulant drugs used in clinical practice with description of
the mode of action and management of therapy in different clinical settings.
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1. Introduction
Anticoagulant drugs directly or indirectly influence coagulation factors and thus inhibit the
initiation and progress of coagulation and fibrin-clot formation. They are classified into two
groups according to the mode of application, namely parenteral and oral drugs. Among the
latter, vitamin K antagonists (most often warfarin) were the only available oral anticoagulants
and were widely used for almost a century. In recent years, new oral anticoagulant drugs
became available that directly target either factor IIa or Xa [1].
This chapter provides an overview of both parenteral and oral anticoagulant drugs used in
clinical practice with a description of the mode of action and management of therapy in
different clinical settings.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Parenteral anticoagulant drugs
2.1. Unfractionated heparin
Unfractionated heparin (UFH) binds antithrombin—a physiological inhibitor of coagulation—
and accelerates its inhibitory action against coagulation factors II and X and in minor degrees
also factors IX, XI and XII [2, 3]. UFH is active in a parenteral form only and therefore
administered by intravenous (i.v.) infusion [2]. It is used for the treatment of acute thrombo-
embolic events. One of the major disadvantages of UFH is its binding to plasma proteins and
endothelial cells making its anticoagulant effect unpredictable [2, 3]. Treatment with UFH
must, therefore, be regularly monitored with activated partial thromboplastin time (APTT).
Due to different sensitivities of APTT reagents the therapeutic APTT range must be determined
by each laboratory and must correspond to heparin anti-factor Xa activity between 0.3 and
0.7 IU/mL [4–6]. Treatment is initiated with UFH bolus of 80 U/kg i.v. and continued with
continuous infusion of 18 U/kg body mass/h [7]. Dosage must be adjusted according to the
APTT result. At the beginning of treatment, laboratory monitoring is needed several times a
day, the first one 6 h after UFH initiation. The two most important non-hemorrhagic side
effects of UFH treatment are osteoporosis and thrombocytopenia [2].
2.2. Low-molecular weight heparin
Low-molecular weight heparin (LMWH) is obtained by various methods of fractionation or
depolymerization of polymeric UFH [8]. Because LMWHs differ in molecular mass, they also
differ in pharmacological characteristics and anticoagulant effects [9]. All LMWHs inhibit
coagulation factors II and X. Among the most commonly used LMWHs for treatment and the
prevention of acute thromboembolic events are dalteparin (Fragmin®), enoxaparin (Clexane®)
and nadroparin (Fraxiparine® and Fraxiparine forte®) in the form of subcutaneous injections.
They can also be used as a bridging therapy in patients with high thromboembolic risk during
a period when these patients cannot receive oral anticoagulants. Therapeutic dose is deter-
mined according to the patient’s body weight [2] (Table 1).
For prevention of venous thromboembolism (VTE), lower (prophylactic) doses of LMWH are
used [2] (Table 2). The adequate LMWH dose is selected according to the risk. Prophylactic
doses are used in some patients during the interim cessation of oral anticoagulant therapy
above all in the first days after large interventions.
The most important advantage of LMWH over UFH is the lower degree of binding to plasma
proteins and endothelial cells making their pharmacokinetics and anticoagulant effects pre-
dictable [10, 11]. Regular laboratory monitoring with coagulation tests is therefore not needed,
except in patients with kidney disease and patients with very low (under 45 kg) or very high
(above 120 kg) body weight [2]. Although APTT may be mildly prolonged during LMWH
therapy it cannot be used for monitoring. The chromogenic anti-Xa is the test of choice for the
determination of plasma LMWH concentration [12]. The LMWH dose should be adjusted to
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0.5–1.0 IU/mL 4 h after the last LMWH dose when administered twice daily or to 1.0–2.0
IU/mL 5–6 h after the last dose when administered once daily [13, 14]. The two main
non-hemorrhagic side effects of LMWH therapy are osteopenia and thrombocytopenia; how-
ever, both these side effects are considerably rarer compared to UFH therapy [2].
Therapeutic dose
LMWH Twice daily Once daily
Dalteparin (Fragmin®) 100 IU/kg BW/12 h sc 200 IU/kg BW/24 h sc
46–56 kg 5.000 IU/12 h sc 10.000 IU/24 h sc
57–68 kg 6.000 IU/12 h sc 12.500 IU/24 h sc
69–82 kg 7.500 IU/12 h sc 15.000 IU/24 h sc
82–120 kg 100 IU/kgBW/12 h sc 18.000 IU/24 h sc
Enoksaparin (Clexane®) 1 mg/kg BW/12 h sc 1.5 mg/kg BW/24 h sc
45–54 kg 50 mg/12 h sc 80 mg/24 h sc
55–64 kg 60 mg/12 h sc 90 mg/24 h sc
65–74 kg 70 mg/12 h sc 100 mg/24 h sc
75–84 kg 80 mg/12 h sc 120 mg/24 h sc
85–94 kg 90 mg/12 h sc 135 mg/24 h sc
94–120 kg 100 mg/12 h sc 150 mg/24 h sc
Nadroparin (Fraxiparine®) 0.1 ml/10 kg BW /12 h sc (Fraxiparine FORTE®) 0.1 ml/10 kg BW/24 h sc
50–59 kg 0.5 ml/12 h sc 0.5 ml/24 h sc
60–69 kg 0.6 ml/12 h sc 0.6 ml/24 h sc
70–79 kg 0.7 ml/12 h sc 0.7 ml/24 h sc
80–89 kg 0.8 ml/12 h sc 0.8 ml/24 h sc
90–120 kg 0.9 ml/12 h sc 0.9 ml/24 h sc
IU: International Units, BW: body weight, sc: subcutaneously.
Table 1. LMWH therapeutic doses according to body weight.
LMWH Low prophylactic dose (moderate VTE risk) High prophylactic dose (high VTE risk)
Dalteparin 2500 IU/24 h sc 5000 IU/24 h sc
Enoxaparin 20 mg/24 h sc 40 mg/24 h sc
Nadroparin 0.3 ml/24 h sc 0.4 ml/24 h sc at BW ≤ 70 kg
0.6 ml/24 h sc at BW > 70 kg
IU: International Units, BW: body weight, sc: subcutaneously, VTE: venous thromboembolism.
Table 2. Prophylactic doses of LMWH.




Fondaparin (Arixtra®) is a synthetic pentasaccharide that closely resembles the pentasacch-
aride naturally occurring in the UFH and LMWH. It is an antithrombin-mediated factor Xa
inhibitor that is devoid of any anti-factor IIa (thrombin) activity [15]. It is used for treating
patients with acute coronary syndrome and heparin-induced thrombocytopenia. It is indicated
also for certain patients with thrombophlebitis in a fixed dose of 2.5 mg daily s.c. Laboratory
monitoring is not needed; however, if necessary fondaparin levels should only be determined
using assays that use known fondaparin concentrations to generate their calibration curve. The
use of fondaparin in patients with creatinine clearance below 30 mL/min is contraindicated [2].
2.4. Hirudin
Hirudin is a naturally occurring peptide in the salivary glands of medicinal leeches that
irreversibly inhibits thrombin. Lepirudin, a recombinant hirudin derived from yeast cells, was
used in clinical practice but is no longer available. Instead, the synthetic analog—bivalirudin
(Angiox®)—with a short half-life is used at percutaneous coronary interventions and for
treating patients with heparin-induced thrombocytopenia. The use of bivalirudin in patients
with creatinine clearance below 30 mL/min is contraindicated [16].
2.5. Argatroban
Argatroban (Argatra®) is a synthetic reversible direct thrombin inhibitor. It is metabolized
solely in the liver and is, therefore, suitable for patients with renal failure. It is used in patients
with heparin-induced thrombocytopenia. Treatment with argatroban requires laboratory mon-
itoring with activated partial thromboplastin time (APTT) and the dose adjusted to reach 1.5–
3.0 times prolonged baseline APTT, but should not exceed 100 s [17].
3. Oral anticoagulants
3.1. Vitamin K antagonists
The vitamin K-dependent coagulation factors II, VII, IX and X require γ-carboxylation for their
procoagulant activity. Treatment with vitamin K antagonists results in the hepatic production
of partially carboxylated and decarboxylated proteins with reduced coagulant activity. Among
the most commonly used vitamin K antagonists are warfarin and acenocoumarol. Although
vitamin K antagonists are absorbed quickly their full effect develops after about 5 days when
the activity of all vitamin K-dependent coagulation factors is reduced [1].
Warfarin therapy requires regular laboratory monitoring with prothrombin time (PT). Due to
different sensitivities of thromboplastin reagents used for PT measurement the results are
expressed as the International Normalized Ratio (INR). For the majority of indications the
target INR range falls between 2.0 and 3.0. In certain patient populations, for example, in
patients with mechanical heart valves, the target range is 2.5–3.5 INR. A rare non-hemorrhagic
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side effect of vitamin K antagonist therapy is skin necrosis that develops at therapy initiation
and is a consequence of acute thrombosis of subcutaneous venules and capillaries [1].
3.2. Direct oral anticoagulants
3.2.1. Dabigatran
Dabigatran etexilate (Pradaxa®) is a low-molecular weight prodrug that exhibits no pharma-
cological activity. After oral administration, dabigatran etexilate is converted to its active form,
dabigatran, a potent, competitive and reversible direct thrombin inhibitor [18]. The binding of
dabigatran to thrombin is specific and selective and includes both free and thrombus-bound
thrombin. Maximal blood concentration of dabigatran is reached after 1–3 h after the intake
[18]. About 35% of the drug is bound to plasma proteins. Eighty percent of dabigatran is
excreted through the kidneys [18]. Dabigatran half-life is 14–17 h [18]. It is given in fixed doses
of either 150 or 110 mg twice daily in patients with atrial fibrillation and 150 mg twice daily in
patients with VTE [19, 20]. Prophylactic doses after total hip or knee replacement are 220 or
150 mg once daily with only half the dose given as the first dose after surgery [21].
The anticoagulant effect of dabigatran is predictive and, therefore, requires no regular labora-
tory monitoring. During dabigatran therapy, APTT and thrombin time (TT) are prolonged, but
these two tests can only offer a rough approximation of dabigatran blood concentration. In
certain situations when dabigatran concentration needs to be assessed, a specific test must be
used, such as modified thrombin time or a chromogenic assay [22, 23].
3.2.2. Rivaroxaban
Rivaroxaban (Xarelto®) directly inhibits factor Xa. It selectively binds both free and prothrom-
bin complex bound factor Xa and in this way inhibits thrombin and clot formation. Peak blood
concentration is achieved after 1–3 h after drug ingestion. As much as 95% of the drug is bound
to plasma protein. One-third of the drug is excreted through kidneys, the other two-thirds are
metabolized in the liver. The drug half-life is 8–13 h [1, 24]. Therapeutic doses are 20 and 15 mg
once daily for patients with atrial fibrillation [25]. Patients with VTE are treated with 15 mg
twice daily for the first 3 weeks, followed by 20 mg once daily [26, 27]. The drug must always
be ingested with food. The prophylactic dose for patients with total hip or knee replacement is
10 mg once daily [28, 29].
No laboratory monitoring of therapy is needed due to the predictive effect of the drug.
Rivaroxaban prolongs PT; however, when an assessment of the drug blood level is needed, an
anti-Xa test calibrated to rivaroxaban should be used [30].
3.2.3. Apixaban
Apixaban (Eliquis®) directly and reversibly inhibits factor Xa. Maximal blood concentration of
the drug is achieved 3–4 h after ingestion. As much as 87% of the drug is bound to blood
protein. Twenty-seven percent of the drug is excreted through kidneys and the remainder
through the liver. The drug half-life is 12 h [31]. Patients with atrial fibrillation are treated with
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5 or 2.5 mg twice daily [32]. Patients with VTE are treated with 10 mg twice daily for the first
7 days followed by 5 mg daily [33]. The prophylactic dose for patients with total hip or knee
replacement is 2.5 mg twice daily [34].
No laboratory monitoring of therapy is needed due to the predictive effect of the drug.
Apixaban unreliably prolongs APTT and PT. When an assessment of the drug blood level is
needed, an anti-Xa test calibrated to apixaban should be used [35].
3.2.4. Edoxaban
Edoxaban directly inhibits factor Xa. Maximal blood concentration of the drug is achieved 1–
2 h after the ingestion. About 40–59% of the drug is bound to plasma protein. Roughly 35% of
the drug is excreted through the kidneys and the remainder through the liver. The drug half-
life is 9–14 h. Therapeutic doses are 60 and 30 mg daily for patients with atrial fibrillation and
VTE. The prophylactic dose for patients with total hip or knee replacement is 30 mg once daily.
Edoxaban prolongs APTT and PT, but for a quantitative assessment of the drug level, an anti-
Xa test calibrated to edoxaban must be utilized [36, 37].
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